The Effectiveness of Resistance Training for Patients With Degenerative Arthritis After Surgery (NCT07696195) | Clinical Trial Compass
CompletedNot Applicable
The Effectiveness of Resistance Training for Patients With Degenerative Arthritis After Surgery
Taiwan24 participantsStarted 2025-03-01
Plain-language summary
Osteoarthritis is a common degenerative disease that significantly impacts mobility and disability in older adults. This pilot randomized controlled study aimed to examine the effects of a three-month resistance training program on lower limb muscular endurance, balance performance, pain, and quality of life among patients who had undergone unilateral total knee arthroplasty. Twenty-four participants were randomly assigned to either the experimental group receiving resistance training or the control group receiving routine postoperative rehabilitation. The study evaluates and compares the effectiveness of these interventions to provide insights into incorporating resistance training into postoperative nursing care and recovery programs.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of osteoarthritis requiring first-time unilateral lower limb total joint arthroplasty
* No planned surgery on the contralateral limb
* Clear consciousness and ability to communicate in Mandarin or Taiwanese
* Independent ambulation before surgery
* Adequate vision and hearing (with correction if needed)
* Community-dwelling status
* Willing to participate in this study
Exclusion Criteria:
* Inability to ambulate independently
* Medical contraindications to exercise
* Severe musculoskeletal conditions other than osteoarthritis
* Same-day admission and surgery
* Bilateral joint arthroplasty
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Lower Extremity Muscle Endurance
Timeframe: A higher number of completed stands means a better outcome (better lower extremity muscular endurance). To ensure safety for postoperative patients, a four-legged walker is placed in front of the chair during testing.